Hiroaki Iwata

3.2k total citations
102 papers, 1.8k citations indexed

About

Hiroaki Iwata is a scholar working on Pathology and Forensic Medicine, Rheumatology and Genetics. According to data from OpenAlex, Hiroaki Iwata has authored 102 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pathology and Forensic Medicine, 50 papers in Rheumatology and 47 papers in Genetics. Recurrent topics in Hiroaki Iwata's work include Autoimmune Bullous Skin Diseases (55 papers), Urticaria and Related Conditions (46 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (45 papers). Hiroaki Iwata is often cited by papers focused on Autoimmune Bullous Skin Diseases (55 papers), Urticaria and Related Conditions (46 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (45 papers). Hiroaki Iwata collaborates with scholars based in Japan, Germany and United States. Hiroaki Iwata's co-authors include Hideyuki Ujiie, Hiroshi Shimizu, Wataru Nishie, Ken Natsuga, Ralf J. Ludwig, Kentaro Izumi, Detlef Zillikens, Yasuo Kitajima, Jun Yamagami and Hiroshi Koga and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and PLoS ONE.

In The Last Decade

Hiroaki Iwata

94 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroaki Iwata Japan 23 1.2k 963 892 275 210 102 1.8k
Hideyuki Ujiie Japan 23 1.2k 1.0× 1.0k 1.0× 950 1.1× 140 0.5× 261 1.2× 130 1.8k
Akihiko Shibaki Japan 24 666 0.6× 484 0.5× 573 0.6× 367 1.3× 281 1.3× 43 1.6k
Hideo Yaoita Japan 22 1.1k 0.9× 545 0.6× 603 0.7× 190 0.7× 345 1.6× 88 2.0k
C. Prost‐Squarcioni France 20 753 0.6× 583 0.6× 531 0.6× 51 0.2× 160 0.8× 50 1.2k
Loı̈c Vaillant France 18 893 0.8× 524 0.5× 756 0.8× 122 0.4× 94 0.4× 44 1.8k
Ana María Abreu Vélez United States 16 553 0.5× 333 0.3× 337 0.4× 94 0.3× 83 0.4× 104 928
Johannes S. Kern Germany 24 814 0.7× 360 0.4× 336 0.4× 124 0.5× 430 2.0× 83 2.0k
Ramzy S. Labib United States 23 3.0k 2.6× 2.0k 2.1× 1.7k 1.9× 260 0.9× 189 0.9× 38 3.5k
Makoto Inaoki Japan 16 416 0.4× 204 0.2× 289 0.3× 900 3.3× 348 1.7× 41 1.6k
Michael S. Howard United States 18 429 0.4× 231 0.2× 217 0.2× 111 0.4× 90 0.4× 104 1.0k

Countries citing papers authored by Hiroaki Iwata

Since Specialization
Citations

This map shows the geographic impact of Hiroaki Iwata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Iwata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Iwata more than expected).

Fields of papers citing papers by Hiroaki Iwata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Iwata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Iwata. The network helps show where Hiroaki Iwata may publish in the future.

Co-authorship network of co-authors of Hiroaki Iwata

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Iwata. A scholar is included among the top collaborators of Hiroaki Iwata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Iwata. Hiroaki Iwata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Schmid, Peter, Heather L. McArthur, Baojun Xu, et al.. (2024). LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial. Annals of Oncology. 35. S1212–S1213. 5 indexed citations
4.
Mizutani, Yoko, et al.. (2024). Diacron-Reactive Oxygen Metabolites Levels Are Initially Elevated in Patients with Bullous Pemphigoid. SHILAP Revista de lepidopterología. 4(4). 100282–100282. 1 indexed citations
5.
Ozeki, Takeshi, Ken Muramatsu, Kentaro Izumi, et al.. (2023). Association of Genetic Variants of HLA-DQA1 with Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors. Journal of Investigative Dermatology. 143(11). 2219–2225.e5. 4 indexed citations
6.
Yamagami, Jun, Takeru Funakoshi, Ryo Tanaka, et al.. (2022). Rituximab therapy for intractable pemphigus: A multicenter, open‐label, single‐arm, prospective study of 20 Japanese patients. The Journal of Dermatology. 50(2). 175–182. 4 indexed citations
7.
Iwata, Hiroaki, Yosuke Mai, Keisuke Imafuku, et al.. (2021). Super‐resolution imaging detects BP180 autoantigen in immunoglobulin M pemphigoid. The Journal of Dermatology. 49(3). 374–378. 8 indexed citations
8.
Fujimura, Y, Mika Watanabe, Yasuaki Kobayashi, et al.. (2021). Hair follicle stem cell progeny heal blisters while pausing skin development. EMBO Reports. 22(7). e50882–e50882. 9 indexed citations
9.
Pipi, Elena, Anika Kasprick, Hiroaki Iwata, et al.. (2021). Multiple Modes of Action Mediate the Therapeutic Effect of Intravenous IgG in Experimental Epidermolysis Bullosa Acquisita. Journal of Investigative Dermatology. 142(6). 1552–1564.e8. 4 indexed citations
10.
Iwata, Hiroaki, et al.. (2021). Clinical characteristics and outcomes of bullous pemphigoid patients with versus without oral prednisolone treatment. The Journal of Dermatology. 48(4). 502–510. 5 indexed citations
11.
Vorobyev, Artem, Stephanie Goletz, Hiroaki Iwata, et al.. (2021). Pathogenic Autoantibody Derived from Regulatory T Cell‒Deficient Scurfy Mice Targets Type VII Collagen and Leads to Epidermolysis Bullosa Acquisita‒Like Blistering Disease. Journal of Investigative Dermatology. 142(3). 980–984.e4. 1 indexed citations
12.
Ujiie, Hideyuki, et al.. (2020). Prevalence of infectious diseases in patients with autoimmune blistering diseases. The Journal of Dermatology. 47(4). 378–384. 3 indexed citations
13.
Hundt, Jennifer E., Hiroaki Iwata, Mario Pieper, et al.. (2020). Visualization of autoantibodies and neutrophils in vivo identifies novel checkpoints in autoantibody-induced tissue injury. Scientific Reports. 10(1). 10 indexed citations
14.
Ujiie, Hideyuki, et al.. (2020). Epitope spreading possibly from BP230 to the NC16A domain of BP180 preceding disease progression in bullous pemphigoid. The Journal of Dermatology. 47(7). e255–e257. 3 indexed citations
15.
Morizane, Shin, Toshihisa Hamada, Tomoko Miyake, et al.. (2019). The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T‐cell lymphoma. The Journal of Dermatology. 46(11). 967–977. 8 indexed citations
16.
Ujiie, Hideyuki, Hiroaki Iwata, Jun Yamagami, et al.. (2019). Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita). The Journal of Dermatology. 46(12). 1102–1135. 42 indexed citations
17.
Ujiie, Hideyuki, et al.. (2018). Clinical and immunological features of pemphigus relapse. British Journal of Dermatology. 180(6). 1498–1505. 18 indexed citations
18.
Iwata, Hiroaki & Hideyuki Ujiie. (2017). Complement‐independent blistering mechanisms in bullous pemphigoid. Experimental Dermatology. 26(12). 1235–1239. 22 indexed citations
19.
Iwata, Hiroaki, et al.. (2007). Multiple metastases of destructive basal cell carcionoma to the lung and liver. Skin Cancer. 22(1). 57–61. 1 indexed citations
20.
Kakimoto, Kensaku, Motoya Katsuki, Takao Hirofuji, Hiroaki Iwata, & Tomohiro Koga. (1988). Isolation of T cell line capable of protecting mice against collagen-induced arthritis.. The Journal of Immunology. 140(1). 78–83. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hideyuki Ujiie Breakdown of academic impact, for papers by Akihiko Shibaki Breakdown of academic impact, for papers by Hideo Yaoita Breakdown of academic impact, for papers by C. Prost‐Squarcioni Breakdown of academic impact, for papers by Loı̈c Vaillant Breakdown of academic impact, for papers by Ana María Abreu Vélez Breakdown of academic impact, for papers by Johannes S. Kern Breakdown of academic impact, for papers by Ramzy S. Labib Breakdown of academic impact, for papers by Makoto Inaoki Breakdown of academic impact, for papers by Michael S. Howard
Rankless by CCL
2026